Total Valuation
Clal Biotech has a market cap or net worth of ₪40.62M. The enterprise value is 61.33M.
Market Cap₪40.62M
Enterprise Value61.33M
Share Statistics
Clal Biotech has 156,846,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding156,846,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Clal Biotech’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -44.02%.
Return on Equity (ROE)-0.66
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-44.02%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee5.72K
Profits Per Employee-91.23K
Employee Count146
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Clal Biotech is ―. Clal Biotech’s PEG ratio is 0.05.
PE Ratio―
PS Ratio57.10
PB Ratio2.36
Price to Fair Value2.36
Price to FCF-11.71
Price to Operating Cash Flow-9.00
PEG Ratio0.05
Income Statement
In the last 12 months, Clal Biotech had revenue of 835.00K and earned -13.32M in profits. Earnings per share was -0.08.
Revenue835.00K
Gross Profit364.00K
Operating Income-18.41M
Pretax Income-20.17M
Net Income-13.32M
EBITDA-19.83M
Earnings Per Share (EPS)-0.08
Cash Flow
In the last 12 months, operating cash flow was -3.95M and capital expenditures 0.00, giving a free cash flow of -3.95M billion.
Operating Cash Flow-3.95M
Free Cash Flow-3.95M
Free Cash Flow per Share-0.03
Dividends & Yields
Clal Biotech pays an annual dividend of 22.372, resulting in a dividend yield of ―
Dividend Per Share22.372
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change-9.93%
50-Day Moving Average28.85
200-Day Moving Average31.50
Relative Strength Index (RSI)50.52
Average Volume (3m)153.57K
Important Dates
Clal Biotech upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Clal Biotech as a current ratio of 0.14, with Debt / Equity ratio of 87.92%
Current Ratio0.14
Quick Ratio0.14
Debt to Market Cap0.34
Net Debt to EBITDA-0.81
Interest Coverage Ratio-149.69
Taxes
In the past 12 months, Clal Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Clal Biotech EV to EBITDA ratio is -3.21, with an EV/FCF ratio of -15.66.
EV to Sales76.34
EV to EBITDA-3.21
EV to Free Cash Flow-15.66
EV to Operating Cash Flow-15.66
Balance Sheet
Clal Biotech has ₪1.69M in cash and marketable securities with ₪17.75M in debt, giving a net cash position of -₪16.07M billion.
Cash & Marketable Securities₪1.69M
Total Debt₪17.75M
Net Cash-₪16.07M
Net Cash Per Share-₪0.10
Tangible Book Value Per Share₪0.15
Margins
Gross margin is 0.00%, with operating margin of -2205.03%, and net profit margin of -1595.09%.
Gross Margin0.00%
Operating Margin-2205.03%
Pretax Margin-2415.57%
Net Profit Margin-1595.09%
EBITDA Margin-2374.97%
EBIT Margin-2400.84%
Analyst Forecast
The average price target for Clal Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast59.27%
EPS Growth Forecast78.63%